Kirk Christopher J. 4

4 · Kezar Life Sciences, Inc. · Filed Jul 26, 2023

Form 4

Period: 2023-07-24

DirectorCEO

Transactions

Disposition to Issuer
Stock Option (right to buy)
2023-07-24−87,500→ 0 total
Exercise: $22.85Exp: 2029-01-05→ Common Stock (87,500 underlying)
Disposition to Issuer
Stock Option (right to buy)
2023-07-24−125,000→ 0 total
Exercise: $3.29Exp: 2030-01-11→ Common Stock (125,000 underlying)
Disposition to Issuer
Stock Option (right to buy)
2023-07-24−260,000→ 0 total
Exercise: $5.45Exp: 2031-01-07→ Common Stock (260,000 underlying)
Award
Stock Option (right to buy)
2023-07-24+87,500→ 87,500 total
Exercise: $2.28Exp: 2029-01-05→ Common Stock (87,500 underlying)
Award
Stock Option (right to buy)
2023-07-24+125,000→ 125,000 total
Exercise: $2.28Exp: 2030-01-11→ Common Stock (125,000 underlying)
Award
Stock Option (right to buy)
2023-07-24+260,000→ 260,000 total
Exercise: $2.28Exp: 2031-01-07→ Common Stock (260,000 underlying)
Disposition to Issuer
Stock Option (right to buy)
2023-07-24−170,000→ 0 total
Exercise: $14.55Exp: 2032-01-04→ Common Stock (170,000 underlying)
Disposition to Issuer
Stock Option (right to buy)
2023-07-24−190,000→ 0 total
Exercise: $6.84Exp: 2033-01-07→ Common Stock (190,000 underlying)
Award
Stock Option (right to buy)
2023-07-24+170,000→ 170,000 total
Exercise: $2.28Exp: 2032-01-04→ Common Stock (170,000 underlying)
Award
Stock Option (right to buy)
2023-07-24+190,000→ 190,000 total
Exercise: $2.28Exp: 2033-01-07→ Common Stock (190,000 underlying)

Footnotes (6)

[F1]Fully vested and exercisable.
[F2]On July 24, 2023, the option originally granted to the Reporting Person was amended to reduce the exercise price to $2.28 per share. All of the other terms of the option remain unchanged.
[F3]One forty-eighth (1/48th) of the shares vested or shall vest on a monthly basis commencing on January 1, 2020, subject to the Reporting Person continuing to provide service through each such date.
[F4]One forty-eighth (1/48th) of the shares vested or shall vest on a monthly basis commencing on January 1, 2021, subject to the Reporting Person continuing to provide service through each such date.
[F5]One forty-eighth (1/48th) of the shares vested or shall vest on a monthly basis commencing on January 5, 2022, subject to the Reporting Person continuing to provide service through each such date.
[F6]One forty-eighth (1/48th) of the shares vested or shall vest on a monthly basis commencing on January 8, 2023, subject to the Reporting Person continuing to provide service through each such date.

Documents

1 file